Patents by Inventor Tolga Sutlu

Tolga Sutlu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NATURAL KILLER (NK) CELLS EXPRESSING AN ANTIGEN-SPECIFIC FUNCTIONAL T CELL RECEPTOR (TCR) COMPLEX, METHODS FOR PRODUCTION THEREOF, AND METHODS FOR THERAPEUTIC USE THEREOF
    Publication number: 20240100095
    Abstract: The invention provides modified Natural Killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex. These NK cells are used for T cell receptor (TCR) gene therapy in order to circumvent any risk of mispairing of the TCR ? and ? chains and to provide Major Histocompatibility Complex (MHC)-restricted antigen-specific cytotoxicity to the NK cells. The invention additionally provides methods for producing the modified NK cells, therapeutic compositions including the modified NK cells, and methods for using the modified NK cells in therapy of cancer, viral infections, autoimmunity, and graft versus host disease (GvHD).
    Type: Application
    Filed: September 11, 2023
    Publication date: March 28, 2024
    Applicants: NOVA SOUTHEASTERN UNIVERSITY, SABANCI ÜNIVERSITESI
    Inventors: Tolga SUTLU, Adil Doganay DURU, Batu ERMAN
  • Natural killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex, methods for production thereof, and methods for therapeutic use thereof
    Patent number: 11752172
    Abstract: The invention provides modified Natural Killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex. These NK cells are used for T cell receptor (TCR) gene therapy in order to circumvent any risk of mispairing of the TCR a and ? chains and to provide Major Histocompatibility Complex (MHC)-restricted antigen-specific cytotoxicity to the NK cells. The invention additionally provides methods for producing the modified NK cells, therapeutic compositions including the modified NK cells, and methods for using the modified NK cells in therapy of cancer, viral infections, autoimmunity, and graft versus host disease (GvHD).
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: September 12, 2023
    Assignees: NOVA SOUTHEASTERN UNIVERSITY, SABANCI ÜNIVERSITESI
    Inventors: Tolga Sutlu, Adil Doganay Duru, Batu Erman
  • NATURAL KILLER (NK) CELLS EXPRESSING AN ANTIGEN-SPECIFIC FUNCTIONAL T CELL RECEPTOR (TCR) COMPLEX, METHODS FOR PRODUCTION THEREOF, AND METHODS FOR THERAPEUTIC USE THEREOF
    Publication number: 20190365812
    Abstract: The invention provides modified Natural Killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex. These NK cells are used for T cell receptor (TCR) gene therapy in order to circumvent any risk of mispairing of the TCR a and ? chains and to provide Major Histocompatibility Complex (MHC)-restricted antigen-specific cytotoxicity to the NK cells. The invention additionally provides methods for producing the modified NK cells, therapeutic compositions including the modified NK cells, and methods for using the modified NK cells in therapy of cancer, viral infections, autoimmunity, and graft versus host disease (GvHD).
    Type: Application
    Filed: January 4, 2018
    Publication date: December 5, 2019
    Applicants: NOVA SOUTHEASTERN UNIVERSITY, SABANCI ÜNIVERSITESI
    Inventors: Tolga SUTLU, Adil Doganay DURU, Batu ERMAN
  • Enhanced Gene Delivery to Natural Killer Cells, Hematopoietic Stem Cells and Macrophages
    Publication number: 20190262309
    Abstract: The present invention comprises a method of downregulating intracellular defenses by administering (5Z)-7-Oxozeaenol. This allows for improved delivery of RNA based gene vectors to natural killer, stem and macrophage cells. The resulting cells can be used in adoptive cell transfer therapies. Also provided are methods of treating virally induced inflammation via administration of (5Z)-7-Oxozeaenol together with an anti viral therapeutic.
    Type: Application
    Filed: September 30, 2016
    Publication date: August 29, 2019
    Applicant: Vycellix, Inc
    Inventors: Evren Alici, Adil Duru, Tolga Sutlu